COVID-19 vaccines

COVID-19 vaccines aim to prevent COVID-19 disease by triggering an immune response.

COVID-19 vaccines are being developed following the same legal requirements for qualitysafety and efficacy as for all other vaccines.

Like all vaccines, the effects of COVID-19 vaccines are tested first in the laboratory, including in animals, and then in human volunteers.

European Medicines Agency (EMA), the agency in charge of evaluation and supervision of medicinal products in the EU, evaluates COVID-19 vaccines against the same high standards as for all other vaccines before they can be released for use. Read more on the Approval of vaccines in the European Union.

As for all vaccines, EMA will continually monitor side effects in people who have received COVID-19 vaccines: see Monitoring vaccine safety and reporting side effects.

EMA will identify and evaluate new information that arises on the benefits and safety of COVID-19 vaccines promptly, once the vaccines are being used to help control the pandemic.

Read more

Publication

Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA and the UK

Technical report -

Publication

Key aspects regarding the introduction and prioritisation of COVID-19 vaccination in the EU/EEA and the UK

Technical report -

External links